Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas.

Molecular cancer therapeutics - 1 Sept 2008

Smalley Keiran S M, Lioni Mercedes, Dalla Palma Maurizia, Xiao Min, Desai Brijal, Egyhazi Suzanne, Hansson Johan, Wu Hong, King Alastair J, Van Belle Patricia, Elder David E, Flaherty Keith T, Herlyn Meenhard, Nathanson Katherine L

Abstract excerpt

Recent studies have shown that there is a considerable heterogeneity in the response of melanoma cell lines to MEK and BRAF inhibitors. In the current study, we address whether dysregulation of cyclin-dependent kinase 4 (CDK4) and/or cyclin D1 contribute to the BRAF inhibitor resistance of melano...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cyclin D1
Share to Cyclin-Dependent Kinase 4

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Amplification

Share to Glutamic Acid

Share to Imidazoles

Share to Melanoma

Share to Proto-Oncogene Proteins B-raf

Share to Valine

Source

Open in PubMed Open full text

Identifiers

PMID: 18790768
DOI: 10.1158/1535-7163.MCT-08-0431
PMCID: PMC2651569

Genes

BRAF
CDK4
CCND1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-18790768-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas.PMID 18790768Read ↗

Co-targeting BRAF and cyclin dependent kinases 4/6 for BRAF mutant cancers.Semantic proximity Read ↗

Identification of a Novel Subgroup of Melanomas with KIT/Cyclin-Dependent Kinase-4 OverexpressionSemantic proximity Read ↗

An update on the implications of cyclin D1 in melanomasSemantic proximity Read ↗

[Molecular background of BRAF inhibitor induced resistance in BRAFV600E mutant melanoma cell lines].Semantic proximity Read ↗

The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in MelanomaSemantic proximity Read ↗

Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous MelanomaSemantic proximity Read ↗

Upregulation of MicroRNA-1246 Is Associated with BRAF Inhibitor Resistance in Melanoma Cells with Mutant BRAF.Semantic proximity Read ↗

PDE4D drives rewiring of the MAPK pathway in BRAF-mutated melanoma resistant to MAPK inhibitors.Semantic proximity Read ↗

MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21Semantic proximity Read ↗

Loss of CDKN 2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK 4/6 inhibitor PD 0332991 in melanoma cell linesSemantic proximity Read ↗

Cyclin D1 promotes radioresistance through regulation of RAD51 in melanomaSemantic proximity Read ↗

Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for MelanomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.